NCT05073926 Rifampicin Resistance in S. Aureus During and After Treatment for Latent Tuberculosis
| NCT ID | NCT05073926 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Region Skane |
| Condition | Latent Tuberculosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2021-09-30 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2021-09-30 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Two commonly used treatments for latent tuberculosis infection are either 4 months rifampicin or 6-9 months isoniazid. The invistigators will study the risk of acquisition of rifampicin resistance in commensal Staphylococcus aureus in persons treated with rifampicin versus in persons treated with isoniazide. Through repeated swab cultures before, during, and after treatment the investigators will also investigate potential accumulation of mutations associated with rifampicin resistance over time. Finally, household contacts to persons with rifampicin-resistant S. aureus will be examined to investigate whether onward transmission of rifampicin-resistant S. aureus occurs within households.
Eligibility Criteria
Inclusion Criteria: * diagnosed with latent tuberculosis * prescribed either 4 months rifampicin or 6-9 months isoniazide * informed consent Exclusion Criteria: * none
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05073926 clinical trial?
This trial is open to participants of all sexes, aged 16 Years or older, studying Latent Tuberculosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05073926 currently recruiting?
Yes, NCT05073926 is actively recruiting participants. Contact the research team at anton.reepalu@med.lu.se for enrollment information.
Where is the NCT05073926 trial being conducted?
This trial is being conducted at Malmö, Sweden.
Who is sponsoring the NCT05073926 clinical trial?
NCT05073926 is sponsored by Region Skane. The trial plans to enroll 100 participants.